6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 07 Dec 2022
- Reporting date
- 07 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,818 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 901-925 of 1,000 matching filings.
Per page
25
Current page
37
6-K
File 001-15170
TRANSFER OF TREASURY SHARES
- Filing date
- 05 Dec 2022
- Reporting date
- 05 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 02 Dec 2022
- Reporting date
- 02 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER
- Filing date
- 02 Dec 2022
- Reporting date
- 02 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA FILE ACCEPTED FOR MOMELOTINIB
- Filing date
- 02 Dec 2022
- Reporting date
- 02 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Dec 2022
- Reporting date
- 01 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES
- Filing date
- 25 Nov 2022
- Reporting date
- 25 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP US UPDATE
- Filing date
- 22 Nov 2022
- Reporting date
- 22 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Nov 2022
- Reporting date
- 21 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING INTERIM REVIEW
- Filing date
- 15 Nov 2022
- Reporting date
- 15 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
3
File 001-38266
3 filing
- Filing date
- 14 Nov 2022
- Reporting date
- 07 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
SCHEDULE 13D/A
- Filing date
- 14 Nov 2022
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK UPDATE: ZEJULA 2L IN US
- Filing date
- 14 Nov 2022
- Reporting date
- 14 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU
- Filing date
- 10 Nov 2022
- Reporting date
- 10 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 10 Nov 2022
- Reporting date
- 10 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLOCK LISTING APPLICATION
- Filing date
- 10 Nov 2022
- Reporting date
- 10 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DREAMM-3 PHASE III TRIAL FOR BLENREP
- Filing date
- 07 Nov 2022
- Reporting date
- 07 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
3
File 001-39587
ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
- Filing date
- 04 Nov 2022
- Reporting date
- 16 Jun 2021
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D
ACQUISITION OF BENEFICIAL OWNERSHIP
- Filing date
- 04 Nov 2022
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP
- Filing date
- 03 Nov 2022
- Reporting date
- 03 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
3RD QUARTER RESULTS
- Filing date
- 02 Nov 2022
- Reporting date
- 02 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK RSV VACCINE: US FDA PRIORITY REVIEW
- Filing date
- 02 Nov 2022
- Reporting date
- 02 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Nov 2022
- Reporting date
- 01 Nov 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW
- Filing date
- 28 Oct 2022
- Reporting date
- 28 Oct 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP
- Filing date
- 28 Oct 2022
- Reporting date
- 28 Oct 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing